Drug intelligence / Profile preview

OC901

Development stage: Preclinical
Lead developer: Oncocross
Modality: Small Molecules

Overview

OC901 is an investigational small molecule drug candidate being developed by Oncocross for the treatment of neurodegenerative disorders. Discovered using Oncocross's proprietary AI-driven drug discovery platform, RAPTOR AI, which analyzes transcriptome-level gene expression data to identify optimal drug-disease matches, OC901 is currently in the preclinical stage of development.

Beyond the preview

Go deeper on OC901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OC901.

Explore the full profile